Inflexion Private Equity Partners LLP (“Inflexion”) is delighted to announce that it has launched a Healthcare Advisory Board to help shape its investment strategy and drive value across healthcare investments, both in the UK and internationally.
The Board is comprised of:
- Dee Athwal, pharma and biotech adviser for over 15 years, CEO of Complement Therapeutics and previously held senior roles at Capella Bioscience and UCB
- John Beighton, Chair of Acino and Advanz and previously a board member at Zentiva and CEO of AMCo and Mercury Pharma
- Jan Egberts, Chair of Viroclinics, PhotoCure (PHO.OL), NordicNanovector (NANO.OL) and previously CEO of OctoPlus (OCTO), Agendia, Chair of Mölnlycke Healthcare and member of the Global Executive Board of J&J Medical
- Jane Griffiths, NXD at Johnson Matthey and BAE Systems, Chair of Redx Pharma, and former leadership roles at Janssen and Global Head of Actelion
- Steve Kent, Chair of Phlexglobal, 4ways and Pharmaspectra; former Chair of CRF Health; and a Board member at Parexel
- Rob Scott, formerly Chief Medical Officer and Head of Development at AbbVie, and held senior roles at Amgen and Pfizer
- Charles Woler, Chair at Sygnature Discovery, Chair or non-executive director at various life science businesses in Europe and US; former CEO of Roche France and CEO of Cadus Pharmaceuticals
Inflexion currently has a dedicated team of 11 professionals focused on healthcare investing in the UK and across Europe. It has a number of healthcare companies in its current portfolio including Rosemont Pharmaceuticals, CNX Therapeutics, Pharmaspectra and ELCG.
Healthcare has been one of our core areas of focus since inception, and the last two years have cast a spotlight on its importance globally. We are privileged to work with some of the leading innovators in this space, through our portfolio and our wider network, and are delighted to formalise many of these relationships through this Advisory Board.
Contact us
Please contact us if you have any media enquiries
